Filing Flows

Filing Flows › Companies › Syndax Pharmaceuticals › Cash flow

Syndax Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$27.3M in Q3 2026 · −$177M over twelve months

Operating cash flow−$27.3M
Free cash flow−$27.3M

Analysis

In Q3 2026, Syndax Pharmaceuticals generated −$27.3M of operating cash flow. That is $43.3M more than in Q3 2025 (−$70.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$177M; the largest uses were operating cash flow ($177M), other investing ($73.4M); besides operations, cash came from other financing ($245M), shares issued ($24.7M); the cash balance rose by $19.0M.

Operating cash flow was −$27.3M against net income of −$49.4M. The largest differences: accrued liabilities +$21.3M, stock-based pay +$15.3M, inventory −$6.0M.

Free cash flow

Syndax Pharmaceuticals: free cash flow by quarterSyndax Pharmaceuticals: free cash flow by quarter−$57.4MQ4 2024−$95.2MQ1 2025−$87.8MQ2 2025−$70.5MQ3 2025−$69.5MQ4 2025−$50.3MQ1 2026−$30.3MQ2 2026−$27.3MQ3 2026
Operating cash flow less capital spending.
Syndax Pharmaceuticals: operating cash flow against capital spendingSyndax Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$57.4M$0Q4 2024−$95.2M$0Q1 2025−$87.8M$0Q2 2025−$70.5M$0Q3 2025−$69.5M$0Q4 2025−$50.3M$0Q1 2026−$30.3M$0Q2 2026−$27.3M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$27.3M, Capital spending $0.

Capital allocation, year by year

Syndax Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearSyndax Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow $29.1MFY2021: Shares issued $6.3MFY2021: Capital spending −$129K$35.5MFY2021FY2022: Operating cash flow −$134MFY2022: Shares issued $11.5M$11.5MFY2022FY2023: Operating cash flow −$161MFY2023: Shares issued $5.1M$5.1MFY2023FY2024: Operating cash flow −$275MFY2024: Shares issued $8.0M$8.0MFY2024FY2025: Operating cash flow −$323MFY2025: Shares issued $12.1MFY2025: Capital spending −$187K$12.1MFY2025
Over these 5 years operating cash flow totalled −$863M; the largest uses were operating cash flow ($892M) and capital spending ($316K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$427M
Debt$344M
Net cash$83.0M
Due within a year$350M
Cash runway2.4 years

Syndax Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$177M a year at the current rate against $427M of cash and investments: a runway of about 2.4 years; $350M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

Syndax Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Syndax Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$201MOther investing−$176MOperating cash flow−$27.3MShares issued$3.2MOther financing−$13K
Syndax Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Syndax Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$245MOperating cash flow−$177MOther investing−$73.4MShares issued$24.7MCash drawn (+) / kept (−)−$19.0M

From profit to cash

Syndax Pharmaceuticals: net income to operating cash flow, Q3 2026Syndax Pharmaceuticals: net income to operating cash flow, Q3 2026Net income−$49.4MDepreciation & amortization$6.0MStock-based pay$15.3MReceivables−$1.8MInventory−$6.0MPayables−$1.3MAccrued liabilities$21.3MPrepaid and other assets−$354KOperating cash flow−$27.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$27.3M$3.2M$201M−$27.3M
Q2 2026−$30.3M$8.8M−$206M−$30.3M
Q1 2026−$50.3M$7.5M$4.0M−$50.3M
Q4 2025−$69.5M$5.3M−$18.0M−$69.5M
Q3 2025−$70.5M$6.4M−$8.2M−$70.5M
Q2 2025−$87.8M$83K$45.4M−$87.8M
Q1 2025−$95.2M$385K$90K−$95.2M
Q4 2024−$57.4M$3.1M−$21.1M−$57.4M

Syndax Pharmaceuticals: income statement and cash flow

Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%. The chart follows the revenue to costs, profit and cash.

Syndax Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.